Literature DB >> 21234523

Suppressor of cytokine signaling 1 interacts with oncogenic lymphocyte-specific protein tyrosine kinase.

Srividya Venkitachalam1, Fu-Yu Chueh, King-Fu Leong, Samantha Pabich, Chao-Lan Yu.   

Abstract

Lymphocyte-specific protein tyrosine kinase (Lck) plays a key role in T cell signal transduction and is tightly regulated by phosphorylation and dephosphorylation. Lck can function as an oncoprotein when overexpressed or constantly activated by mutations. Our previous studies showed that Lck-induced cellular transformation could be suppressed by enforced expression of suppressor of cytokine signaling 1 (SOCS1), a SOCS family member involved in the negative feedback control of cytokine signaling. We observed attenuated Lck kinase activity in SOCS1-expressing cells, suggesting an important role of SOCS in regulating Lck functions. It remains largely unknown whether and how SOCS proteins interact with the oncogenic Lck kinase. Here, we report that among four SOCS family proteins, SOCS1, SOCS2, SOCS3 and CIS (cytokine-inducible SH2 domain containing protein), SOCS1 has the highest affinity in binding to the oncogenic Lck kinase. We identified the positive regulatory phosphotyrosine 394 residue in the kinase domain as the key interacting determinant in Lck. Additionally, the Lck kinase domain alone is sufficient to bind SOCS1. While the SH2 domain in SOCS1 is important in its association with the oncogenic Lck kinase, other functional domains may also contribute to overall binding affinity. These findings provide important mechanistic insights into the role of SOCS proteins as tumor suppressors in cells transformed by oncogenic protein tyrosine kinases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21234523      PMCID: PMC3031786          DOI: 10.3892/or.2011.1144

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  28 in total

Review 1.  Suppressors of cytokine signalling (SOCS) in the immune system.

Authors:  Warren S Alexander
Journal:  Nat Rev Immunol       Date:  2002-06       Impact factor: 53.106

2.  The tumor suppressor activity of SOCS-1.

Authors:  Robert Rottapel; Subburaj Ilangumaran; Christopher Neale; Jose La Rose; Jenny M-Y Ho; Melody H-H Nguyen; Dwayne Barber; Patrice Dubreuil; Paulo de Sepulveda
Journal:  Oncogene       Date:  2002-06-27       Impact factor: 9.867

Review 3.  The STATs of cancer--new molecular targets come of age.

Authors:  Hua Yu; Richard Jove
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

4.  CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2.

Authors:  A Sasaki; H Yasukawa; T Shouda; T Kitamura; I Dikic; A Yoshimura
Journal:  J Biol Chem       Date:  2000-09-22       Impact factor: 5.157

5.  The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.

Authors:  T Iwamoto; T Senga; Y Naito; S Matsuda; Y Miyake; A Yoshimura; M Hamaguchi
Journal:  Oncogene       Date:  2000-09-28       Impact factor: 9.867

Review 6.  The influence of the src-family kinases, Lck and Fyn, on T cell differentiation, survival and activation.

Authors:  Rose Zamoyska; Albert Basson; Andrew Filby; Giuseppe Legname; Matthew Lovatt; Benedict Seddon
Journal:  Immunol Rev       Date:  2003-02       Impact factor: 12.988

7.  Negative regulation of FAK signaling by SOCS proteins.

Authors:  Enbo Liu; Jean-François Côté; Kristiina Vuori
Journal:  EMBO J       Date:  2003-10-01       Impact factor: 11.598

8.  SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer.

Authors:  Biao He; Liang You; Kazutsugu Uematsu; Keling Zang; Zhidong Xu; Amie Y Lee; Joseph F Costello; Frank McCormick; David M Jablons
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-14       Impact factor: 11.205

9.  CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation.

Authors:  A Suzuki; T Hanada; K Mitsuyama; T Yoshida; S Kamizono; T Hoshino; M Kubo; A Yamashita; M Okabe; K Takeda; S Akira; S Matsumoto; A Toyonaga; M Sata; A Yoshimura
Journal:  J Exp Med       Date:  2001-02-19       Impact factor: 14.307

Review 10.  Dysregulation of the protein tyrosine kinase LCK in lymphoproliferative disorders and in other neoplasias.

Authors:  M B Majolini; M Boncristiano; C T Baldari
Journal:  Leuk Lymphoma       Date:  1999-10
View more
  7 in total

1.  Low expression of SOCS-1 and SOCS-3 is a poor prognostic indicator for gastric cancer patients.

Authors:  Guanghua Li; Jianbo Xu; Zhao Wang; Yujie Yuan; Yin Li; Shirong Cai; Yulong He
Journal:  J Cancer Res Clin Oncol       Date:  2014-09-28       Impact factor: 4.553

2.  Engagement of T-cell antigen receptor and CD4/CD8 co-receptors induces prolonged STAT activation through autocrine/paracrine stimulation in human primary T cells.

Authors:  Fu-Yu Chueh; Chao-Lan Yu
Journal:  Biochem Biophys Res Commun       Date:  2012-08-23       Impact factor: 3.575

3.  Nuclear localization of lymphocyte-specific protein tyrosine kinase (Lck) and its role in regulating LIM domain only 2 (Lmo2) gene.

Authors:  Srividya Venkitachalam; Fu-Yu Chueh; Chao-Lan Yu
Journal:  Biochem Biophys Res Commun       Date:  2011-12-27       Impact factor: 3.575

4.  Nuclear localization of pyruvate dehydrogenase complex-E2 (PDC-E2), a mitochondrial enzyme, and its role in signal transducer and activator of transcription 5 (STAT5)-dependent gene transcription.

Authors:  Fu-Yu Chueh; King-Fu Leong; Robert J Cronk; Srividya Venkitachalam; Samantha Pabich; Chao-Lan Yu
Journal:  Cell Signal       Date:  2011-03-17       Impact factor: 4.315

5.  Protein degradation machinery is present broadly during early development in the sea urchin.

Authors:  Vanesa Zazueta-Novoa; Gary M Wessel
Journal:  Gene Expr Patterns       Date:  2014-06-22       Impact factor: 1.224

6.  Nuclear lymphocyte-specific protein tyrosine kinase and its interaction with CR6-interacting factor 1 promote the survival of human leukemic T cells.

Authors:  Shahrooz Vahedi; Fu-Yu Chueh; Sujoy Dutta; Bala Chandran; Chao-Lan Yu
Journal:  Oncol Rep       Date:  2015-05-19       Impact factor: 3.906

7.  Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways.

Authors:  Denise Cecil; Kyong Hwa Park; Benjamin Curtis; Lauren Corulli; Mary Nora Disis
Journal:  J Immunother Cancer       Date:  2021-03       Impact factor: 13.751

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.